InterPAD - DETAILS

cytarabine, 147-94-4, Ara-C, Cytosine arabinoside, Aracytidine, Arabinocytidine, Cytarabinoside, Spongocytidine, Aracytin, Cytosar-U, Depocyt, Udicil, Arabinofuranosylcytosine, Arabitin, Aracytine, Cytarabina, Tarabine, Arafcyt, Erpalfa, 1-beta-D-Arabinofuranosylcytosine, arabinocytosine, Cytarabinum, Cytosine beta-D-arabinofuranoside, DepoCyte, Arabinosylcytosine, Cytarabin, Cytosar, Cytosinearabinoside, Citarabina, Depocyt (liposomal), beta-D-Arabinosylcytosine, Cytosine arabinofuranoside, Alexan, Cytosine beta-D-arabinoside, 4-Amino-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one, Cytarabinum [INN-Latin], Arabinoside C, 1beta-D-Arabinosylcytosine, Citarabina [INN-Spanish], Cytosine-1-beta-D-arabinofuranoside, AraC, Cytosine arabinose, 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone, 1beta-Arabinofuranasylcytosine, Iretin, Cytosine 1-beta-D-arabinofuranoside, 1beta-D-Arabinofuranosylcytosine, 1-beta-D-Arabinofaranosylcytosine, beta-Arabinosylcytosine, Ara-Cytidine, U 19920A, Beta-cytosine arabinoside, Cytosine-beta-arabinoside, Cytosine-beta-D-arabinofuranoside, cytarabine liposome, 1-Arabinofuranosylcytosine, CHX 3311, CCRIS 913, U-19,920, 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one, Arabinofuranosyl Cytidine, Cytosine, 1-beta-D-arabinosyl-, 1-beta-D-Arabinosylcytosine, HSDB 3049, 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, EINECS 205-705-9, 1-(arabinofuranosyl)cytosine, Cyclocide, Cytosine, 1-beta-D-arabinofuranosyl-, NSC 287459, UNII-04079A1RDZ, 1-beta-arabinofuranosylcytosine, U-19920, Cytosine |A-D-Arabinofuranoside, DTXSID3022877, CHEBI:28680, AI3-52329, (beta-D-Arabinofuranosyl)cytosine, 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin, 04079A1RDZ, 2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl-, MFCD00066487, CHEMBL803, NSC-287459, MK 8242, 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon, 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one, C9H13N3O5, DTXCID702877, 2(1H)-Pyrimidinone, 4-amino-1-.beta.-D-arabinofuranosyl-, AR3, Cytonal, NCI-C04728, VYXEOS COMPONENT CYTARABINE, 1-beta-D-arabinofuranosyl-cytosine, 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine, AC-1075, beta-Ara C, Cytarabine [USAN:USP:INN:BAN:JAN], NCGC00093356-03, 2(1H)-Pyrimidinone, 4-amino-1-y-D-arabinofuranosyl- [CAS], Cytarbel, (Arabinofuranosyl)cytosine, Cytarabinum (INN-Latin), Citarabina (INN-Spanish), CYTARABINE (MART.), CYTARABINE [MART.], CYTARABINE (USP-RS), CYTARABINE [USP-RS], Citozar, ara-Cytosine, Cytosine arabinoside (VAN), Tarabine PFS, CYTARABINE (EP MONOGRAPH), CYTARABINE (USP IMPURITY), CYTARABINE [EP MONOGRAPH], CYTARABINE [USP IMPURITY], Cytosine-1-beta-arabinofuranoside, CYTARABINE (USP MONOGRAPH), CYTARABINE [USP MONOGRAPH], 69-74-9, Ara-cell, Cytarabine (USAN:USP:INN:BAN:JAN), cytarabine liposome injection, Arabinosyl Cytosine, Cytosine, beta-D-arabinoside, CAS-147-94-4, SMR000449317, Depocyt (TN), Arabinoside, Cytosine, 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one, Cytartbine, Arabine, 1-.beta.-D-Arabinofuranosylcytosine, Cytarabine; 4-amino-1-beta-d-arabinofuranosylpyrimidin-2(1H)-one, SR-01000075773, NSC287459, 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech], 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech], 1-(beta-d-arabinofuranosyl)cytosine, 1-.beta.-D-arabinofuranosyl-cytosine, 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone, U-19920 A, cytarabine ocphosphate, 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside, beta -arabinosylcytosine, Arabinofuranosylcytosine?, CYTARABINE [MI], U 19920, CYTARABINE [INN], CYTARABINE [JAN], CYTARABINE [HSDB], CYTARABINE [USAN], beta -cytosine arabinoside, beta -D-arabinosylcytosine, Cytosine-beta -arabinoside, CYTARABINE [VANDF], SCHEMBL3140, 1beta -D-Arabinosylcytosine, CYTARABINE [WHO-DD], CYTARABINE [WHO-IP], BIDD:PXR0139, Lopac0_000316, MLS000758310, MLS001066340, MLS001424023, 1-beta-D-Arabinosyl-Cytosine, BIDD:GT0371, CYTARABINE [EMA EPAR], Cytosine, beta -D-arabinoside, 1beta -Arabinofuranasylcytosine, Cytarabine (JP17/USP/INN), GTPL4827, 1-ss-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-amino-1beta-D-arabinofuranosyl-, CYTARABINE [ORANGE BOOK], SCHEMBL22591193, SCHEMBL23152019, 1beta -D-Arabinofuranosylcytosine, BETA-CYTOSINE, ARABINOSIDE, L01BC01, Cytosine, 1-beta -D-arabinosyl-, 1-beta -d-arabinofuranosylcytosine, 1-beta-D-arabinofuranosyl cytosine, Cytosine-beta -D-arabinofuranoside, HMS2051K19, HMS2090A18, HMS2230M16, HMS3713N12, 1-beta -D-Arabinofaranosylcytosine, CYTARABINE LIPOSOME [VANDF], CYTARABINUM [WHO-IP LATIN], BCP02876, Tox21_111203, Tox21_301971, BDBM50087289, CCG-51297, s1648, AKOS007930145, AKOS015896896, AM84428, Cytosine, 1-beta -D-arabinofuranosyl-, DB00987, KS-5063, NC00070, SDCCGSBI-0050304.P002, NCGC00093356-04, NCGC00093356-05, NCGC00093356-06, NCGC00093356-19, NCGC00142483-02, NCGC00255381-01, 1(BETA-D-ARABINOFURANOSYL)CYTOSINE, BA164339, HY-13605, SRI-10828-19, SRI-10828-20, SRI-10828_24, WR-28453, SL-000002, U 19,920A, C2035, NS00005949, SW197450-5, C02961, D00168, EN300-118320, 1-BETA-D-ARABINOFURANOSYLCYTOSINE; ARA-C, A808710, Q180983, SR-01000721860, J-520199, J-700005, J-700166, SR-01000075773-3, SR-01000075773-5, SR-01000721860-6, U 19,920, 1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl, BRD-K33106058-001-07-7, BRD-K33106058-003-20-6, 1-BETA-D-ARABINOSYL-4-AMINO-2(1H)PYRIMIDINONE, 2(1H)-Pyrimidinone, 4-amino-1beta -D-arabinofuranosyl-, Cytosine -D-arabinofuranoside;Cytosine Arabinoside;Ara-C, Z1511499171, 2(1H)-Pyrimidinone, 4-amino-1-beta -D-arabinofuranosyl-, Cytarabine, European Pharmacopoeia (EP) Reference Standard, Cytarabine, United States Pharmacopeia (USP) Reference Standard, Cytosine beta-D-arabinofuranoside, crystalline, >=90% (HPLC), Cytosine beta-D-arabinofuranoside, Vetec(TM) reagent grade, 90%, Cytarabine, Pharmaceutical Secondary Standard; Certified Reference Material, 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one, Cytosine -D-arabinofuranoside hydrochloride;Cytosine Arabinoside hydrochloride;Ara-C hydrochloride

Name	Cytarabine
PubChem CID	6253
Molecular Weight	243.22g/mol
Synonyms	cytarabine, 147-94-4, Ara-C, Cytosine arabinoside, Aracytidine, Arabinocytidine, Cytarabinoside, Spongocytidine, Aracytin, Cytosar-U, Depocyt, Udicil, Arabinofuranosylcytosine, Arabitin, Aracytine, Cytarabina, Tarabine, Arafcyt, Erpalfa, 1-beta-D-Arabinofuranosylcytosine, arabinocytosine, Cytarabinum, Cytosine beta-D-arabinofuranoside, DepoCyte, Arabinosylcytosine, Cytarabin, Cytosar, Cytosinearabinoside, Citarabina, Depocyt (liposomal), beta-D-Arabinosylcytosine, Cytosine arabinofuranoside, Alexan, Cytosine beta-D-arabinoside, 4-Amino-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one, Cytarabinum [INN-Latin], Arabinoside C, 1beta-D-Arabinosylcytosine, Citarabina [INN-Spanish], Cytosine-1-beta-D-arabinofuranoside, AraC, Cytosine arabinose, 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone, 1beta-Arabinofuranasylcytosine, Iretin, Cytosine 1-beta-D-arabinofuranoside, 1beta-D-Arabinofuranosylcytosine, 1-beta-D-Arabinofaranosylcytosine, beta-Arabinosylcytosine, Ara-Cytidine, U 19920A, Beta-cytosine arabinoside, Cytosine-beta-arabinoside, Cytosine-beta-D-arabinofuranoside, cytarabine liposome, 1-Arabinofuranosylcytosine, CHX 3311, CCRIS 913, U-19,920, 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one, Arabinofuranosyl Cytidine, Cytosine, 1-beta-D-arabinosyl-, 1-beta-D-Arabinosylcytosine, HSDB 3049, 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, EINECS 205-705-9, 1-(arabinofuranosyl)cytosine, Cyclocide, Cytosine, 1-beta-D-arabinofuranosyl-, NSC 287459, UNII-04079A1RDZ, 1-beta-arabinofuranosylcytosine, U-19920, Cytosine \|A-D-Arabinofuranoside, DTXSID3022877, CHEBI:28680, AI3-52329, (beta-D-Arabinofuranosyl)cytosine, 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin, 04079A1RDZ, 2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl-, MFCD00066487, CHEMBL803, NSC-287459, MK 8242, 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon, 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one, C9H13N3O5, DTXCID702877, 2(1H)-Pyrimidinone, 4-amino-1-.beta.-D-arabinofuranosyl-, AR3, Cytonal, NCI-C04728, VYXEOS COMPONENT CYTARABINE, 1-beta-D-arabinofuranosyl-cytosine, 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine, AC-1075, beta-Ara C, Cytarabine [USAN:USP:INN:BAN:JAN], NCGC00093356-03, 2(1H)-Pyrimidinone, 4-amino-1-y-D-arabinofuranosyl- [CAS], Cytarbel, (Arabinofuranosyl)cytosine, Cytarabinum (INN-Latin), Citarabina (INN-Spanish), CYTARABINE (MART.), CYTARABINE [MART.], CYTARABINE (USP-RS), CYTARABINE [USP-RS], Citozar, ara-Cytosine, Cytosine arabinoside (VAN), Tarabine PFS, CYTARABINE (EP MONOGRAPH), CYTARABINE (USP IMPURITY), CYTARABINE [EP MONOGRAPH], CYTARABINE [USP IMPURITY], Cytosine-1-beta-arabinofuranoside, CYTARABINE (USP MONOGRAPH), CYTARABINE [USP MONOGRAPH], 69-74-9, Ara-cell, Cytarabine (USAN:USP:INN:BAN:JAN), cytarabine liposome injection, Arabinosyl Cytosine, Cytosine, beta-D-arabinoside, CAS-147-94-4, SMR000449317, Depocyt (TN), Arabinoside, Cytosine, 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one, Cytartbine, Arabine, 1-.beta.-D-Arabinofuranosylcytosine, Cytarabine; 4-amino-1-beta-d-arabinofuranosylpyrimidin-2(1H)-one, SR-01000075773, NSC287459, 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech], 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech], 1-(beta-d-arabinofuranosyl)cytosine, 1-.beta.-D-arabinofuranosyl-cytosine, 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone, U-19920 A, cytarabine ocphosphate, 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside, beta -arabinosylcytosine, Arabinofuranosylcytosine?, CYTARABINE [MI], U 19920, CYTARABINE [INN], CYTARABINE [JAN], CYTARABINE [HSDB], CYTARABINE [USAN], beta -cytosine arabinoside, beta -D-arabinosylcytosine, Cytosine-beta -arabinoside, CYTARABINE [VANDF], SCHEMBL3140, 1beta -D-Arabinosylcytosine, CYTARABINE [WHO-DD], CYTARABINE [WHO-IP], BIDD:PXR0139, Lopac0_000316, MLS000758310, MLS001066340, MLS001424023, 1-beta-D-Arabinosyl-Cytosine, BIDD:GT0371, CYTARABINE [EMA EPAR], Cytosine, beta -D-arabinoside, 1beta -Arabinofuranasylcytosine, Cytarabine (JP17/USP/INN), GTPL4827, 1-ss-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-amino-1beta-D-arabinofuranosyl-, CYTARABINE [ORANGE BOOK], SCHEMBL22591193, SCHEMBL23152019, 1beta -D-Arabinofuranosylcytosine, BETA-CYTOSINE, ARABINOSIDE, L01BC01, Cytosine, 1-beta -D-arabinosyl-, 1-beta -d-arabinofuranosylcytosine, 1-beta-D-arabinofuranosyl cytosine, Cytosine-beta -D-arabinofuranoside, HMS2051K19, HMS2090A18, HMS2230M16, HMS3713N12, 1-beta -D-Arabinofaranosylcytosine, CYTARABINE LIPOSOME [VANDF], CYTARABINUM [WHO-IP LATIN], BCP02876, Tox21_111203, Tox21_301971, BDBM50087289, CCG-51297, s1648, AKOS007930145, AKOS015896896, AM84428, Cytosine, 1-beta -D-arabinofuranosyl-, DB00987, KS-5063, NC00070, SDCCGSBI-0050304.P002, NCGC00093356-04, NCGC00093356-05, NCGC00093356-06, NCGC00093356-19, NCGC00142483-02, NCGC00255381-01, 1(BETA-D-ARABINOFURANOSYL)CYTOSINE, BA164339, HY-13605, SRI-10828-19, SRI-10828-20, SRI-10828_24, WR-28453, SL-000002, U 19,920A, C2035, NS00005949, SW197450-5, C02961, D00168, EN300-118320, 1-BETA-D-ARABINOFURANOSYLCYTOSINE; ARA-C, A808710, Q180983, SR-01000721860, J-520199, J-700005, J-700166, SR-01000075773-3, SR-01000075773-5, SR-01000721860-6, U 19,920, 1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl, BRD-K33106058-001-07-7, BRD-K33106058-003-20-6, 1-BETA-D-ARABINOSYL-4-AMINO-2(1H)PYRIMIDINONE, 2(1H)-Pyrimidinone, 4-amino-1beta -D-arabinofuranosyl-, Cytosine -D-arabinofuranoside;Cytosine Arabinoside;Ara-C, Z1511499171, 2(1H)-Pyrimidinone, 4-amino-1-beta -D-arabinofuranosyl-, Cytarabine, European Pharmacopoeia (EP) Reference Standard, Cytarabine, United States Pharmacopeia (USP) Reference Standard, Cytosine beta-D-arabinofuranoside, crystalline, >=90% (HPLC), Cytosine beta-D-arabinofuranoside, Vetec(TM) reagent grade, 90%, Cytarabine, Pharmaceutical Secondary Standard; Certified Reference Material, 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one, Cytosine -D-arabinofuranoside hydrochloride;Cytosine Arabinoside hydrochloride;Ara-C hydrochloride
Drug Type	Small molecule
Formula	C₉H₁₃N₃O₅
SMILES	C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O
InChI	1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
InChIKey	UHDGCWIWMRVCDJ-CCXZUQQUSA-N
CAS Number	147-94-4
ChEMBL ID	CHEMBL803
ChEBI ID	CHEBI:28680
TTD ID	D07XSN
Drug Bank ID	DB00987
KEGG ID	C02961
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Emodin, Cytarabine
Partner Name	Emodin
Disease Info	[ICD-11: 2A60.Z]	Acute myeloid leukemia		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BID	hsa637
	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Phosphorylation	MAPK3	hsa5595
	Down-regulation	Phosphorylation	MTOR	hsa2475
	Down-regulation	Phosphorylation	RPS6KB1	hsa6198
In Vitro Model	HL-60	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_0002
	ARAC-8C	Childhood T acute lymphoblastic leukemia	Homo sapiens (Human)	CVCL_GZ09
	Jurkat	Childhood T acute lymphoblastic leukemia	Homo sapiens (Human)	CVCL_0065
	MOLT-4	Adult T acute lymphoblastic leukemia	Homo sapiens (Human)	CVCL_0013
	CA46	Burkitt lymphoma	Homo sapiens (Human)	CVCL_1101
In Vivo Model	Around 1.5×10⁷ HL-60/H3 cells were subcutaneously injected into the right flank of BALB/C-nude mice.
Result	Emodin and its combination with Ara-C may be considered a promising therapeutic approach in AML and worthy of further investigation.

Pair Name	Brusatol, Cytarabine
Partner Name	Brusatol
Disease Info	[ICD-11: 2A60.Z]	Acute myeloid leukemia		Investigative
Gene Regulation	Down-regulation	Expression	G6PD	hsa2539
Gene Regulation	Down-regulation	Expression	NFE2L2	hsa4780
In Vitro Model	HL-60	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_0002
In Vitro Model	THP-1	Childhood acute monocytic leukemia	Homo sapiens (Human)	CVCL_0006
Result	Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C

Pair Name	Astaxanthin, Cytarabine
Partner Name	Astaxanthin
Disease Info	[ICD-11: 2B33.3]	Acute lymphoblastic leukemia		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BCL-xL	hsa598
	Up-regulation	Expression	CASP3	hsa836
	Up-regulation	Expression	CASP8	hsa841
	Down-regulation	Expression	IL6	hsa3569
	Down-regulation	Expression	TNF	hsa7124
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	NALM-6	Adult B acute lymphoblastic leukemia	Homo sapiens (Human)	CVCL_0092
Result	Co-treatment of ASX and Ara-C has synergism effects on apoptosis pathways, cell proliferation inhibition, and decreased inflammation.

Pair Name	Mitocurcumin, Cytarabine
Partner Name	Mitocurcumin
Disease Info	[ICD-11: 2B33.4]	Leukemia		Investigative
Biological Phenomena	Induction-->Apoptosis and DNA damage
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BCL-xL	hsa598
	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	CHEK1	hsa1111
	Up-regulation	Phosphorylation	H2AX	hsa3014
	Up-regulation	Cleavage	JUN	hsa3725
	Up-regulation	Activity	MAPK14	hsa1432
	Up-regulation	Phosphorylation	MAPK8	hsa5599
	Down-regulation	Expression	MCL1	hsa4170
	Down-regulation	Expression	MYC	hsa4609
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Expression	RAD51	hsa5888
	Down-regulation	Expression	XIAP	hsa331
In Vitro Model	MOLM-13	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_2119
In Vitro Model	HL-60	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_0002
In Vivo Model	A total of 1.5 × 106 MOLM13 cells were injected subcutaneously into the flank region of 6–8 weeks-old NOD/SCID mice. When tumors grew to 150–200 mm3, the mice were randomized into three groups (n = 9/group) followed by intraperitoneal administration of 0.1% DMSO daily, MitoC (2 mg/kg) on alternate days, or cytarabine (20 mg/kg) daily for 12 days.
Result	The data suggest that MitoC exploits stress-induced leukemic oxidative environment to up-regulate JNK/p38 signaling to lead to apoptosis and can potentially overcome Cytarabine resistance via ROS/p21/CHK1 axis.

No.	Title	Href
1	Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo. Cell Physiol Biochem. 2018;48(5):2061-2073. doi: 10.1159/000492544.	`Click`
2	Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C. Biomed Pharmacother. 2021 Oct;142:111652. doi: 10.1016/j.biopha.2021.111652.	`Click`
3	Astaxanthin decreases the growth-inhibitory dose of cytarabine and inflammatory response in the acute lymphoblastic leukemia cell line NALM-6. Mol Biol Rep. 2022 Jul;49(7):6415-6422. doi: 10.1007/s11033-022-07452-8.	`Click`
4	Mitocurcumin utilizes oxidative stress to upregulate JNK/p38 signaling and overcomes Cytarabine resistance in acute myeloid leukemia. Cell Signal. 2024;114:111004. doi:10.1016/j.cellsig.2023.111004	`Click`